Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Samarth Kulkarni. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Samarth Kulkarni har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:CRSP / CRISPR Therapeutics AG | Chief Executive Officer, Director | 207 004 |
US:RPTX / Repare Therapeutics Inc. | Director | 49 000 |
US:BDTX / Black Diamond Therapeutics, Inc. | Director | 15 000 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Samarth Kulkarni. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp BDTX / Black Diamond Therapeutics, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i BDTX / Black Diamond Therapeutics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel BDTX / Black Diamond Therapeutics, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i BDTX / Black Diamond Therapeutics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp RPTX / Repare Therapeutics Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i BDTX / Black Diamond Therapeutics, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel RPTX / Repare Therapeutics Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i BDTX / Black Diamond Therapeutics, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Samarth Kulkarni som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −13 081 | 207 004 | −5,94 | 58,15 | −760 660 | 12 037 283 | |
2025-08-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 220 085 | 12,81 | ||||
2025-03-24 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −10 031 | 195 085 | −4,89 | 41,23 | −413 578 | 8 043 355 | |
2025-03-24 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 19 688 | 205 116 | 10,62 | ||||
2025-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −4 462 | 185 428 | −2,35 | 43,32 | −193 294 | 8 032 741 | |
2025-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 9 000 | 189 890 | 4,98 | ||||
2025-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −9 973 | 180 890 | −5,23 | 42,42 | −423 055 | 7 673 354 | |
2025-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 19 250 | 190 863 | 11,22 | ||||
2025-02-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −18 360 | 171 613 | −9,66 | 55,20 | −1 013 564 | 9 473 896 |
2025-02-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −6 928 | 189 973 | −3,52 | 52,80 | −365 798 | 10 030 574 | |
2025-02-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −11 640 | 196 901 | −5,58 | 55,05 | −640 782 | 10 839 400 |
2025-02-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 13 250 | 208 541 | 6,78 | ||||
2024-12-27 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 13 751 | 195 291 | 7,57 | 16,21 | 222 904 | 3 165 667 | |
2024-12-04 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −15 000 | 181 540 | −7,63 | 55,10 | −826 564 | 10 003 635 |
2024-11-13 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −6 879 | 196 540 | −3,38 | 56,27 | −387 081 | 11 059 306 |
2024-11-13 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −23 121 | 203 419 | −10,21 | 55,43 | −1 281 597 | 11 275 515 |
2024-10-15 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −4 293 | 226 540 | −1,86 | 46,28 | −198 680 | 10 484 271 | |
2024-10-15 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 8 333 | 230 833 | 3,75 | ||||
2024-08-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
G - Gift | −100 000 | 222 500 | −31,01 | ||||
2024-04-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 204 | 208 122 | −0,58 | 60,40 | −72 722 | 12 570 631 |
2024-04-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −18 378 | 209 326 | −8,07 | 59,88 | −1 100 510 | 12 534 839 |
2024-04-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 19 582 | 227 704 | 9,41 | 19,12 | 374 408 | 4 353 700 | |
2024-03-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −9 387 | 208 122 | −4,32 | 73,06 | −685 818 | 15 205 477 |
2024-03-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −10 613 | 217 509 | −4,65 | 71,97 | −763 810 | 15 653 970 |
2024-03-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 228 122 | 9,61 | 19,12 | 382 400 | 4 361 693 | |
2024-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −4 583 | 208 122 | −2,15 | 74,44 | −341 159 | 15 492 602 | |
2024-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 9 000 | 212 705 | 4,42 | ||||
2024-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −9 802 | 203 705 | −4,59 | 78,26 | −767 105 | 15 941 953 | |
2024-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 19 250 | 213 507 | 9,91 | ||||
2024-02-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | −6 370 | 194 257 | −3,18 | 79,67 | −507 498 | 15 476 455 | |
2024-02-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 13 250 | 200 627 | 7,07 | ||||
2024-02-16 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 100 | 187 377 | −0,58 | 81,66 | −89 831 | 15 302 049 |
2024-02-16 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 951 | 188 477 | −3,06 | 81,04 | −482 257 | 15 273 780 |
2024-02-16 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −12 949 | 194 428 | −6,24 | 79,94 | −1 035 090 | 15 541 777 |
2024-02-16 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 207 377 | 10,67 | 19,12 | 382 400 | 3 965 048 | |
2024-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −700 | 187 377 | −0,37 | 61,10 | −42 770 | 11 448 697 |
2024-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −49 300 | 188 077 | −20,77 | 60,50 | −2 982 803 | 11 379 242 |
2024-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 50 000 | 237 377 | 26,68 | 19,12 | 956 000 | 4 538 648 | |
2024-01-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 000 | 187 377 | −9,64 | 62,50 | −1 250 058 | 11 711 606 |
2024-01-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 207 377 | 10,67 | 19,12 | 382 400 | 3 965 048 | |
2023-06-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 400 | 387 377 | −0,62 | 66,83 | −160 401 | 25 889 877 |
2023-06-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −9 300 | 389 777 | −2,33 | 65,63 | −610 359 | 25 581 065 |
2023-06-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 999 | 399 077 | −1,48 | 64,46 | −386 682 | 25 723 586 |
2023-06-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −7 301 | 405 076 | −1,77 | 63,61 | −464 452 | 25 768 869 |
2023-06-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 412 377 | 6,45 | 19,12 | 478 000 | 7 884 648 | |
2023-04-27 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 393 | 387 377 | −1,12 | 51,45 | −226 021 | 19 930 663 |
2023-04-27 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 607 | 391 770 | −5,00 | 50,50 | −1 040 616 | 19 783 680 |
2023-04-27 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 412 377 | 6,45 | 19,12 | 478 000 | 7 884 648 | |
2023-03-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 281 | 387 377 | −1,34 | 44,78 | −236 506 | 17 348 447 |
2023-03-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −19 719 | 392 658 | −4,78 | 44,37 | −874 997 | 17 423 531 |
2023-03-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 412 377 | 6,45 | 19,12 | 478 000 | 7 884 648 | |
2023-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −4 086 | 387 377 | −1,04 | 43,22 | −176 597 | 16 742 434 | |
2023-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −5 358 | 382 463 | −1,38 | 43,22 | −231 573 | 16 530 051 | |
2023-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 9 000 | 391 463 | 2,35 | ||||
2023-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 11 833 | 387 821 | 3,15 | ||||
2023-03-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 100 | 375 988 | −0,29 | 49,20 | −54 118 | 18 498 083 |
2023-03-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −13 720 | 377 088 | −3,51 | 48,57 | −666 415 | 18 316 107 |
2023-03-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −10 180 | 390 808 | −2,54 | 47,71 | −485 710 | 18 646 309 |
2023-03-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 400 988 | 6,65 | 19,12 | 478 000 | 7 666 891 | |
2023-02-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −6 373 | 375 988 | −1,67 | 48,26 | −307 561 | 18 145 181 | |
2023-02-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 13 250 | 382 361 | 3,59 | ||||
2023-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −23 200 | 369 111 | −5,91 | 51,54 | −1 195 712 | 19 023 723 |
2023-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 800 | 392 311 | −0,46 | 50,60 | −91 086 | 19 852 192 |
2023-01-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 394 111 | 6,77 | 19,12 | 478 000 | 7 535 402 | |
2022-12-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 634 | 369 111 | −1,24 | 41,45 | −192 101 | 15 301 349 |
2022-12-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 366 | 373 745 | −5,17 | 40,81 | −831 189 | 15 253 505 |
2022-12-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 394 111 | 6,77 | 19,12 | 478 000 | 7 535 402 | |
2022-12-08 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 58 233 | 369 111 | 18,73 | 1,81 | 105 402 | 668 091 | |
2022-12-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −19 401 | 310 878 | −5,87 | 52,26 | −1 013 896 | 16 246 484 | |
2022-12-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 40 000 | 330 279 | 13,78 | ||||
2022-11-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 310 | 290 279 | −0,79 | 55,40 | −127 983 | 16 082 589 |
2022-11-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 572 | 292 589 | −1,87 | 54,85 | −305 598 | 16 047 131 |
2022-11-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −17 118 | 298 161 | −5,43 | 53,58 | −917 246 | 15 976 570 |
2022-11-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 315 279 | 8,61 | 19,12 | 478 000 | 6 028 134 | |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −7 188 | 290 279 | −2,42 | 55,69 | −400 333 | 16 166 973 |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −11 312 | 297 467 | −3,66 | 54,97 | −621 774 | 16 350 541 |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 000 | 308 779 | −1,28 | 54,06 | −216 254 | 16 693 673 |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 500 | 312 779 | −0,79 | 52,73 | −131 830 | 16 493 462 |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 5 418 | 315 279 | 1,75 | 19,12 | 103 592 | 6 028 134 | |
2022-10-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 19 582 | 309 861 | 6,75 | 16,21 | 317 424 | 5 022 847 | |
2022-09-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 800 | 290 279 | −0,62 | 64,97 | −116 946 | 18 859 427 |
2022-09-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −23 200 | 292 079 | −7,36 | 64,58 | −1 498 214 | 18 861 936 |
2022-09-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 315 279 | 8,61 | 16,21 | 405 250 | 5 110 673 | |
2022-08-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −163 | 290 279 | −0,06 | 67,64 | −11 025 | 19 634 472 |
2022-08-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 764 | 290 442 | −6,67 | 66,98 | −1 390 669 | 19 452 353 |
2022-08-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 073 | 311 206 | −1,29 | 66,14 | −269 390 | 20 583 320 |
2022-08-31 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 315 279 | 8,61 | 16,21 | 405 250 | 5 110 673 | |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −600 | 290 279 | −0,21 | 77,97 | −46 783 | 22 633 547 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 308 | 290 879 | −1,12 | 76,29 | −252 382 | 22 192 439 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −12 759 | 294 187 | −4,16 | 75,73 | −966 265 | 22 279 370 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −700 | 306 946 | −0,23 | 77,79 | −54 455 | 23 878 219 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −700 | 307 646 | −0,23 | 76,37 | −53 461 | 23 495 848 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −6 933 | 308 346 | −2,20 | 75,64 | −524 402 | 23 322 829 |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 16 667 | 315 279 | 5,58 | 16,21 | 270 172 | 5 110 673 | |
2022-07-29 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 8 333 | 298 612 | 2,87 | 12,57 | 104 746 | 3 753 553 | |
2022-07-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 740 | 290 279 | −1,61 | 62,32 | −295 407 | 18 090 826 |
2022-07-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 260 | 295 019 | −6,43 | 61,42 | −1 244 454 | 18 121 306 |
2022-07-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 25 000 | 315 279 | 8,61 | 12,57 | 314 250 | 3 963 057 | |
2022-05-16 |
|
4 | RPTX |
Repare Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 49 000 | 49 000 | |||||
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −4 153 | 290 279 | −1,41 | 61,08 | −253 665 | 17 730 241 | |
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
M - Exercise | −9 000 | 27 000 | −25,00 | ||||
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 9 000 | 294 432 | 3,15 | ||||
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −5 487 | 285 432 | −1,89 | 62,56 | −343 267 | 17 856 626 | |
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
M - Exercise | −11 834 | 11 833 | −50,00 | ||||
2022-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 11 834 | 290 919 | 4,24 | ||||
2022-02-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
A - Award | 53 000 | 53 000 | |||||
2022-02-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 115 000 | 115 000 | |||||
2021-12-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −17 750 | 58 233 | −23,36 | ||||
2021-12-22 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 17 750 | 279 085 | 6,79 | 1,81 | 32 128 | 505 144 | |
2021-12-07 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −37 818 | 261 335 | −12,64 | 69,17 | −2 615 871 | 18 076 542 | |
2021-12-07 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
M - Exercise | 80 000 | 40 000 | −200,00 | ||||
2021-12-07 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 80 000 | 299 153 | 36,50 | ||||
2021-12-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −779 | 219 153 | −0,35 | 75,10 | −58 503 | 16 458 390 | |
2021-10-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −33 000 | 75 983 | −30,28 | ||||
2021-10-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 43 000 | 43 000 | |||||
2021-10-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 33 000 | 219 932 | 17,65 | 1,81 | 59 730 | 398 077 | |
2021-09-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −787 | 186 932 | −0,42 | 124,83 | −98 241 | 23 334 722 | |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −28 500 | 33 333 | −46,09 | ||||
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
S - Sale | X | −2 482 | 187 719 | −1,30 | 130,51 | −323 926 | 24 499 207 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
S - Sale | X | −6 819 | 190 201 | −3,46 | 129,82 | −885 243 | 24 691 894 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
S - Sale | X | −13 499 | 197 020 | −6,41 | 128,85 | −1 739 346 | 25 386 027 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
S - Sale | X | −4 700 | 210 519 | −2,18 | 127,82 | −600 754 | 26 908 539 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
S - Sale | X | −1 000 | 215 219 | −0,46 | 126,67 | −126 670 | 27 261 791 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Stock |
M - Exercise | 28 500 | 216 219 | 15,18 | 12,57 | 358 245 | 2 717 873 | |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −1 500 | 61 833 | −2,37 | ||||
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 500 | 187 719 | −0,79 | 125,02 | −187 530 | 23 468 629 |
2021-08-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 1 500 | 189 219 | 0,80 | 12,57 | 18 855 | 2 378 483 | |
2021-06-22 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2021-06-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −30 000 | 63 333 | −32,14 | ||||
2021-06-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 488 | 187 719 | −1,82 | 127,51 | −444 755 | 23 936 050 |
2021-06-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −16 129 | 191 207 | −7,78 | 126,86 | −2 046 125 | 24 256 520 |
2021-06-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −10 383 | 207 336 | −4,77 | 125,39 | −1 301 924 | 25 997 861 |
2021-06-17 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 30 000 | 217 719 | 15,98 | 12,57 | 377 100 | 2 736 728 | |
2021-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −779 | 187 719 | −0,41 | 115,80 | −90 208 | 21 737 860 | |
2021-05-14 |
|
4 | RPTX |
Repare Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 21 000 | 21 000 | |||||
2021-04-23 |
|
4 | BDTX |
Black Diamond Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 14 921 | 14 921 | |||||
2021-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
A - Award | 36 000 | 36 000 | |||||
2021-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 100 000 | 100 000 | |||||
2021-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −5 526 | 188 498 | −2,85 | 124,15 | −686 053 | 23 402 027 | |
2021-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 11 833 | 194 024 | 6,49 | ||||
2021-03-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −798 | 182 191 | −0,44 | 130,25 | −103 940 | 23 730 378 | |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 108 983 | −15,51 | ||||
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 304 | 182 989 | −0,71 | 217,44 | −283 542 | 39 789 128 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 708 | 184 293 | −0,92 | 216,50 | −369 782 | 39 899 434 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −1 700 | 186 001 | −0,91 | 214,68 | −364 956 | 39 930 695 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 623 | 187 701 | −2,91 | 213,71 | −1 201 691 | 40 113 581 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −6 525 | 193 324 | −3,26 | 212,75 | −1 388 194 | 41 129 681 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 140 | 199 849 | −1,55 | 211,83 | −665 146 | 42 334 014 |
2021-01-20 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 202 989 | 10,93 | 1,81 | 36 200 | 367 410 | |
2020-12-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (right to buy) |
M - Exercise | −13 800 | 128 983 | −9,67 | ||||
2020-12-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 13 800 | 182 989 | 8,16 | 1,81 | 24 978 | 331 210 | |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 142 783 | −12,29 | ||||
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −600 | 169 189 | −0,35 | 144,97 | −86 982 | 24 527 329 |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 100 | 169 789 | −1,22 | 143,71 | −301 791 | 24 400 377 |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −6 766 | 171 889 | −3,79 | 142,75 | −965 846 | 24 537 155 |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 034 | 178 655 | −2,74 | 141,98 | −714 727 | 25 365 437 |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 500 | 183 689 | −2,91 | 141,17 | −776 435 | 25 931 376 |
2020-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 189 189 | 11,82 | 1,81 | 36 200 | 342 432 | |
2020-12-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −779 | 169 189 | −0,46 | 129,58 | −100 943 | 21 923 511 | |
2020-10-06 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 47 333 | 47 333 | |||||
2020-09-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −779 | 169 968 | −0,46 | 94,15 | −73 343 | 16 002 487 | |
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −779 | 170 747 | −0,45 | 66,26 | −51 617 | 11 313 696 | |
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −17 275 | 162 783 | −9,59 | ||||
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 575 | 171 526 | −3,15 | 65,26 | −363 824 | 11 193 787 |
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −9 300 | 177 101 | −4,99 | 64,61 | −600 873 | 11 442 496 |
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 400 | 186 401 | −1,27 | 63,57 | −152 568 | 11 849 512 |
2020-06-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 17 275 | 188 801 | 10,07 | 1,81 | 31 268 | 341 730 | |
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −10 693 | 180 058 | −5,61 | ||||
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −10 693 | 171 526 | −5,87 | 65,28 | −698 039 | 11 197 217 |
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 10 693 | 182 219 | 6,23 | 1,81 | 19 354 | 329 816 | |
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −4 307 | 190 751 | −2,21 | ||||
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 307 | 171 526 | −2,45 | 65,16 | −280 644 | 11 176 634 |
2020-05-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 4 307 | 175 833 | 2,51 | 1,81 | 7 796 | 318 258 | |
2020-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
A - Award | 35 500 | 35 500 | |||||
2020-03-12 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 142 000 | 142 000 | |||||
2020-03-04 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −794 | 171 526 | −0,46 | 52,74 | −41 876 | 9 046 281 | |
2019-12-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −8 000 | 195 058 | −3,94 | ||||
2019-12-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 8 000 | 172 320 | 4,87 | 1,81 | 14 480 | 311 899 | |
2019-12-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
A - Award | 120 000 | 120 000 | |||||
2019-12-02 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −741 | 164 320 | −0,45 | 71,65 | −53 093 | 11 773 528 | |
2019-09-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −740 | 165 061 | −0,45 | 46,21 | −34 195 | 7 627 469 | |
2019-06-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 203 058 | −8,97 | ||||
2019-06-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 000 | 165 801 | −10,76 | 46,00 | −920 000 | 7 626 846 |
2019-06-19 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 185 801 | 12,06 | 1,81 | 36 200 | 336 300 | |
2019-06-04 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −741 | 165 801 | −0,44 | 35,57 | −26 357 | 5 897 542 | |
2019-05-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 223 058 | −8,23 | ||||
2019-05-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −20 000 | 166 542 | −10,72 | 42,03 | −840 600 | 6 999 760 |
2019-05-01 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 20 000 | 186 542 | 12,01 | 1,81 | 36 200 | 337 641 | |
2019-03-07 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 250 000 | 250 000 | |||||
2019-03-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −748 | 166 542 | −0,45 | 39,97 | −29 898 | 6 656 684 | |
2018-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −21 500 | 243 058 | −8,13 | ||||
2018-12-11 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 21 500 | 167 290 | 14,75 | 1,81 | 38 915 | 302 795 | |
2018-12-03 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −741 | 145 790 | −0,51 | 38,33 | −28 403 | 5 588 131 | |
2018-09-04 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −741 | 146 531 | −0,50 | 56,67 | −41 992 | 8 303 912 | |
2018-06-15 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 109 000 | 109 000 | |||||
2018-06-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
F - Taxes | −741 | 147 819 | −0,50 | 67,13 | −49 743 | 9 923 089 | |
2018-06-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Employee Stock Option (right to buy) |
M - Exercise | −15 000 | 264 558 | −5,37 | ||||
2018-06-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −10 400 | 148 560 | −6,54 | 70,28 | −730 912 | 10 440 797 |
2018-06-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 600 | 158 960 | −2,81 | 67,28 | −309 488 | 10 694 829 |
2018-06-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 15 000 | 163 560 | 10,10 | 1,81 | 27 150 | 296 044 | |
2018-04-18 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | −75 000 | 150 000 | −33,33 | ||||
2018-03-14 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock option (right to buy) |
A - Award | −75 000 | 75 000 | −50,00 | ||||
2018-03-09 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 136 000 | 136 000 | |||||
2017-12-26 |
|
4 | CRSP |
CRISPR Therapeutics AG
Employee Stock Option (right to buy) |
M - Exercise | −15 000 | 279 558 | −5,09 | ||||
2017-12-26 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 15 000 | 148 560 | 11,23 | 1,81 | 27 150 | 268 894 | |
2017-12-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Option (Right to Buy) |
A - Award | 260 000 | 260 000 | |||||
2017-12-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Restricted Stock Units |
A - Award | 26 667 | 133 560 | 24,95 | 19,12 | 509 873 | 2 553 667 | |
2017-08-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 000 | 106 893 | −3,61 | 20,00 | −80 000 | 2 137 860 |
2017-08-30 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −23 154 | 110 893 | −17,27 | 20,09 | −465 162 | 2 227 829 |
2017-05-05 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
A - Award | 100 000 | 100 000 | |||||
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −2 206 | 294 558 | −0,74 | ||||
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 206 | 134 047 | −1,62 | 16,78 | −37 023 | 2 249 684 |
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 2 206 | 136 253 | 1,65 | 1,81 | 3 993 | 246 618 | |
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −3 275 | 296 764 | −1,09 | ||||
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 275 | 134 047 | −2,38 | 16,74 | −54 816 | 2 243 652 |
2017-04-28 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 3 275 | 137 322 | 2,44 | 1,81 | 5 928 | 248 553 | |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −5 115 | 300 039 | −1,68 | ||||
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −5 115 | 134 047 | −3,68 | 16,87 | −86 290 | 2 261 373 |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 5 115 | 139 162 | 3,82 | 1,81 | 9 258 | 251 883 | |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −3 500 | 305 154 | −1,13 | ||||
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 500 | 134 047 | −2,54 | 16,46 | −57 619 | 2 206 776 |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 3 500 | 137 547 | 2,61 | 1,81 | 6 335 | 248 960 | |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −3 000 | 308 654 | −0,96 | ||||
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −3 000 | 134 047 | −2,19 | 17,01 | −51 033 | 2 280 260 |
2017-04-25 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 3 000 | 137 047 | 2,24 | 1,81 | 5 430 | 248 055 | |
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −2 800 | 311 654 | −0,89 | ||||
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 800 | 134 047 | −2,05 | 17,36 | −48 621 | 2 327 686 |
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 2 800 | 136 847 | 2,09 | 1,81 | 5 068 | 247 693 | |
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Stock Options (Right to Buy) |
M - Exercise | −7 258 | 314 454 | −2,26 | ||||
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −2 449 | 134 047 | −1,79 | 18,54 | −45 393 | 2 484 601 |
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
S - Sale | X | −4 809 | 136 496 | −3,40 | 17,54 | −84 361 | 2 394 467 |
2017-04-21 |
|
4 | CRSP |
CRISPR Therapeutics AG
Common Shares |
M - Exercise | 7 258 | 141 305 | 5,41 | 1,81 | 13 137 | 255 762 | |
2016-10-18 | 3 | CRSP |
CRISPR Therapeutics AG
Common Shares |
268 094 | ||||||||
2016-10-18 | 3 | CRSP |
CRISPR Therapeutics AG
Common Shares |
268 094 |